Synthetic genes encoding bovine and human basic tibroblast growth factors (bFGFs) were assembled and cloned using established Escherichiu coli expression plasmids. Transformed E. coli cells were able to synthesize either a fusion protein, comprising the first seven amino acids of p-galactosidase, a linker fragment and bovine FGF, or genomic human bFGF. The two growth factors were purified from E. coli lysates by cation exchange and heparin-Sepharose affinity chromatography. The purified recombinant proteins were biologically active as monitored by their mitogenic activity for bovine aortic endothelial cells and their angiogenic capacity in the rabbit cornea.
INTRODUCTION
The growth of the new capillaries (angiogenesis) is a complex process which involves both the migration and proliferation of vascular endothelial cells (Folkman, 1985) . The vascular endothelium of a normal adult organism rejuvenates only a few times. On the other hand, a rapid turnover can be seen in various pathophysiological responses such as acute inflammation, wound healing, and tumor angiogenesis (Folkman and Klagsbrun, 1987) . Basic FGF (bFGF) has been shown to be a very potent mitogen and chemoattractant for endothelial cells in vitro (for review, see Gospodarowicz et al., 1986) . It stimulates angiogenesis in vivo on the chick chorioallantoic membrane and rabbit cornea (for review, see Folkman and Klagsbrun, 1987) .
Bovine bFGF has been purified and characterized from a wide range of tissues including pituitary, brain, hypothal~us, retina, adrenal gland, thymus, corpus luteum, and kidney (Lobb et al., 1986; Gospodarowicz et al., 1986) . Although the amino acid and nucleotide sequences of both bovine and human bFGF are known (Abraham et al., 1986) , little protein material has up to now been available. It is therefore desirable to produce sufficient quantities of recombinant bFGF to be able to tackle questions concerning the biological role of signals that naturally trigger angiogenesis in vivo or to obtain sufficient growth-factor protein for use as an (essential) component for serum-free cell-culture medium.
Here we report the design, assembly, and expression of synthetic genes encoding bovine and human bFGFs. Since bFGF is a single-chain non glycosylated polypeptide, it seemed reasonable to expect that biolo~cally active material might be produced in E. coli. Two different vector systems were used to obtain synthesis of the factors in fused and unfused forms. An initial step toward optimization of the direct expression of human bFGF was taken by manipulating the N-terminal part of the synthetic gene so as to allow efficient tr~slational initiation in the pJLA503 expression vector.
MATERIALS AND METHODS

(a) Reagents and enzymes
Restriction endonucleases and BSA were purchased from Boehringer Mannheim. Bacteriophage T4 DNA ligase, polynucleotide kinase, PolIk, nucleic-acid-grade agarose, heparin-Sepharose, CLdB;
CM-Sephadex C-50, Bio-Gel-P2, and NAP-10 columns were obtained from Pharmacia. Oligos 1-26 were synthesized using phosphotriester chemistry on the Biosearch model Cyclone oligo synthesizer. Oligos were purified by electrophoresis on 12% to 20% poiyacrylamide gel under denaturing conditions. Gel-purified oligos were eluted from the gel in water and desalted on NAP-10 columns.
(c) Phosphoryiati~ and tigation of oIig~xy~ucle-otides
Oligos used in the assembly of the synthetic bFGF gene were phosphorylated as follows: 500 ng of each purified oligo with the exception of numbers 1, 8, 9, 14, 15, 22, 23 , and 26 were incubated in 10 1.11 of 70 mM Tris . HCl, pH 7.6, 10 mM MgCl,, 5 mM DTT, 10pM ATP, and 0.15 PM [y-3ZP]ATP (specific activity 6000 Ci/mmol) containing 10 units of T4 polynucleotide kinase. After 1 h at 37°C the kinase was inactivated by heating to 95 *C for 2 min. After separating labeled DNA from unincorporated [ y-32P]ATP by chromatography through small columns of Bio-Gel-P2, the following subsets of oligos were mixed for ligation to the fragments A, B, C, and C', respectively: oligos Nos. 1-8, 9-14, 15-22, and 23-26 . The indicated subsets were heated to 80' C for 10 min and then slowly cooled to 25°C over 1 h to allow the complementary strands to anneal.
Each solution was adjusted to 70 mM Tris * HCI pH 7.2, 100 mM NaCl, 10 mM MgCl,, 1 mM EDTA, and 5 mM DTT. Then 0.5 mM ATP T4 DNA ligase was added to 0.8 units per 10 ~1 and the reaction mixture was incubated overnight at 16°C. Fragments A, B, and C were purified in a 7 M ureafl2% polyacryl~ide gel run in 90 mM Tris, 90 mM borate, and 2 mM EDTA. The wet gel was autoradiographed overnight and the detected DNA fragments were electroeluted into dialysis bags. After incubation for 1 h at 50°C the enzyme was inactivated by adding 2 ~1 of 0.5 mM EDTA.
(d) Plasmid construction and DNA cloning
Standard procedures were used for plasmid purilication (Birnboim and Doly, 1979) , transformation (Mandel and Higa, 1970) and DNA sequencing (Sanger et al., 1977) . Large plasmid fragments were separated by agarose gel electrophoresis followed by electroelution on DEAE-NA45 membranes.
(e) Isolation of recombinant basic fibroblast growth factor (1) Cell lysis 250 ml of an appropriate culture was centrifuged for 15 min at 4000 rev./min. and 0" C. The cell pellet was resuspended in 4 ml buffer L (50 mM Tris . HCl, pH 8.0, 10 mM EDTA) containing 25% sucrose. After adding 6 mg lysozyme in 1.2 ml buffer L and 2.4mlof0.25 M EDTA,0.25MTris.HCl,pH 8.0, the mixture was incubated for 1 h at 0' C. Then 10 ml of 2% Triton X-100 in buffer L was added and, following sonication at O"C, soluble and insoluble material was separated by centrifugation for 17 min at 6000 rev./min. The pellet containing bFGF inclusion bodies was washed twice with 2% Triton X-100 in buffer L and used for purification (see subsection 3, below).
(2) Purification of soluble FGF
The supernatant remaining after cell lysis (see subsection I, above) was applied to a CM Sephadex C-50 column (10 ml bed volume, diameter 4 cm, flow rate 100 ml/h, at room temperature), washed with 0.1 M Na. phosphate, pH 6.5, 0.15 M NaCl, and eluted with 0.1 M Na* phosphate, pH 6.5, 0.6 M NaCl. The eluate was applied to heparin-Sepharose column (2 ml bed volume, diameter 1 cm, flow rate 50 ml/h). The column was washed with 10 mM
Tris . HCl, pH 7.0, 0.8 M NaCl and eluted with 10 mM Tris . HCl, pH 7.0, 2.0 M NaCl. The eluate was dialysed against 50 mM ammonium formate and lyophilized.
(3) Preparation of bFGFfrom inclusion bodies
The washed pellet obtained after cell lysis (see subsection 1, above) was solubilized in 10 ml buffer L containing 6 M guanidinium. HCl and 0.25 M DTT and incubated for 2 h at 50°C. Buffer L (30 ml) was then added slowly with vigorous stirring and simultaneous slow cooling to 30°C. After dialyzing against 10 mM Tris . HCl, pH 7.0, 0.8 M NaCl and subsequent centrifugation, the supernatant was applied directly to a heparin-Sepharose column as described above.
(f) Preparation of rabbit anti-bovine basic fibroblast growth factor
A peptide corresponding to the 19 aa (FPPGHFKDPKRLYCKNGGF) near the N terminus of bovine bFGF (Esch et al., 1985) was synthesized by solid-phase methods using a Biosearch peptide synthesizer. The synthetic peptide was purified by reverse-phase HPLC and then coupled to BSA using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC; Shapira et al., 1984) .
Rabbits were immunized with 0.5 mg of the BSApeptide conjugate emulsified with complete Freund's adjuvant. Three weeks later, a booster injection was given using 0.3 mg of the conjugate emulsified in incomplete Freud's adjuvant. Sera were tested by Western blot analysis (see section b, below) using bovine brain-derived bFGF.
(g) SDS-PAGE and silver staining
Growth factor fractions from various purification steps were dialyzed against 50 mM ammonium formate overnight, lyophilized, boiled in sample buffer, and analyzed on SDS-15% PAGE (Laemmli, 1970) . After electrophoresis the polypeptide bands were visualized by silver staining (Oakley et al., 1980) .
(j) In vivo assay
Heparin-Sepharose-purified recombinant bFGF in Elvax polymers (Langer et al., 1986 ) was implanted into rabbit cornea1 pockets as described (Gimbrone et al., 1974; Risau, 1986) .
RESULTS AND DISCUSSION
(h) Western-blot analysis
For Western immunoblotting analysis, electrophoretically separated polypeptides were transferred onto nitrocellulose at 0.3 mA/cm2 in 20 mM Tris, pH 7.4, 150 mM glycine, and 20% methanol overnight (Towbin et al., 1979) . To block nonspecific binding, the nitrocellulose was incubated with PBS containing 3 y0 B SA for 1 h at room temperature and washed twice with PBS containing 0.1 y0 Tween-20.
The first antibody reaction was carried out by incubating the nitrocellulose with a lOOO-fold dilution of the rabbit anti-bovine bFGF antibody in PBS containing 0.1 y0 Tween-20 and 1 y0 BSA for 2 h at room temperature followed by 3 washing steps with PBS containing 0.1% Tween-20. The nitrocellulose was then incubated with a 500-fold dilution of the peroxidase-conjugated goat anti-rabbit IgG antibody for 1 h at room temperature followed by washing.
The immunoreaction was visualized using 0.5 mg/ml diaminobenzidine . HCl in 50 mM Tris' HCl, pH 7.6, 100 mM NaCl, 0.4% nickel sulfate, and 0.01% H,O,.
(i) Proliferation assay
Fractions were assayed for growth factor activity on BAE cells as described (Risau, 1986) . Briefly, cells were resuspended in DMEM supplemented with 4% FCS, glutamine (0.5 mg/ml), and penicillin/streptomycin (100 units/ml), and plated (10000 cells/O.5 ml per well) on 24-well plates. Unattached cells were removed one day later and 0.5 ml of fresh supplemented DMEM containing growth-factor fractions was added. After three days of incubation, cells were detached from the plates using trypsin/EDTA solution and counted in a coulter counter.
(a) Construction of the bovine and human bFGF gene A synthetic gene encoding the 146 aa of bovine bFGF was designed on the basis of the known amino acid sequence (Esch et al., 1985) . The selection of the precise nucleotide sequence for the gene was influenced by the following considerations:
(1) The high frequency of a set of statistically 'preferred' codons among highly expressed E. coli genes; (2) the obvious convenience of introducing unique restriction endonuclease recognition sites into the sequence; and (3) the need to avoid the presence of excessively stable secondary structures in the encoded mRNA, especially in the early part of the cistron. Twenty-two oligos ranging in size from 24 to 52 nt were synthesized, purified, and assembled to form the synthetic bovine bFGF gene (Fig. 1) . To assemble the gene, subsets of oligos were ligated to generate the fragments A, B, and C. These fragments were purified by PAGE under denaturing conditions, phosphorylated, and ligated to appropriately digested, dephosphorylated vectors. The resulting hybrid plasmids were transferred into E. coli cells. Clones containing the predicted DNA inserts as determined by double-digestion of the respective plasmid DNA were selected for the preparation of larger quantities of the A, B, and C fragments, which were subsequently isolated and annealed. The resulting synthetic gene was ligated to EcoRI + HindIIdigested pUC8 and used to transform E. coli HB 10 1.
A clone containing the predicted nucleotide sequence, as determined by Sanger et al. (1977) sequencing, was designated pUC8ABC.
The synthetic gene encoding the 146 aa of the human bFGF was initially constructed by exchanging fragment C of pUC8ABC for a further fragment C' (Fig. 1 ) that was synthesized according to the published sequence of human bFGF (Abraham et al., 1986) . N-terminally extended forms of the gene were constructed by exchanging the first part of the synthetic sequence with appropriate oligo pairs.
(b) Expression of basic fibroblast growth factor
Plasmid pUC12, an M13mp7-derived system (Vieira and Messing, 1982) , was doubly digested with SmaI + HindIII, dephosphorylated, and ligated Prominent polypeptides with apparent M,.s of hairpin loop structure immediately adjacent to the Shine-Dalgarno region (Fig. 2a) . Such a structure would be expected to impinge on translational initiation (see, e.g., McCarthy and Bokelmann, 1988) .
In the case of human bFGF a number of constructs differing in the nature of the N-terminal part of the synthetic gene were subjected to analysis. Extra codons, corresponding to part or all of the N-terminal extension to the 146-aa form of bFGF identified by nucleotide sequencing (Abraham et al., 1986) , were included in these constructs.
One construct encoded the full 155 aa described by Abraham et al. (1986) . The extra N-terminal sequence was borne on an N&I-Hind111 DNA fragment, whereby the codon usage was adjusted to prevent the formation of highly stable secondary structure within the translational initiation region formed upon insertion a of this new synthetic gene into the expression vector pJLA503 (Fig. 2b) . The 155-codon gene, containing the NdeI-Hind111 fragment, was initially subcloned into pCB179 (Schneider and Beck, 1987) . It was subsequently excised as an NdeI-Sal1 fragment and inserted into appropriately cleaved pJLA503. The latter expression vector is one of a series of plasmids derived from pJLl20 1 bearing part of the E. coli atpE TIR (McCarthy et al., 1986; Schauder et al., 1987) . Transcription in these plasmids is initiated by the 1 bacteriophage major pR and pL promoters (in tandem) and is repressed by the product of the plasmid-borne cIts857 gene.
Correct recombinant products, bearing the fused bovine bFGF in pUC12 (LD1/2) and the unfused, fully extended human bFGF in pJLA503 (T36/9), were transferred into E. coli cells (strain Ion-, htpR_) . Transcription of the human bFGF gene was repressed by the A cIts875-coded repressor when cultures of R1180-T36/9 were grown at 30°C. A temperature shift from 30°C to 42°C allowed synthesis of large amounts of human bFGF via inactivation of the A cIts857-coded repressor (Fig. 3) . Cultures of R1180[pJLA503] (vector minus DNA insert) grown at 30' C and 42' C served as controls. The bovine bFGF fusion protein encoded by LD1/2 was expressed constitutively in strain R1180. Recombinant growth factors were purified from E. coli cells using a procedure established for the purification of bFGF from bovine brain (Lobb et al., 1986; Risau et al., 1988) . Cells were lysed by a combination of Triton X-100 and mild lysozyme treatment. Following sonication the extracts were clarilied by centrifugation.
The supernatant was applied to a CM-Sephadex C-50 cation exchange column. The column was washed and growth factor activity eluted using 0.6 M NaCl. Heparin-Sepharose affinity chromatography was used as the second step in purification. Almost all of the extraneous protein present in the Sephadex eluate was separated from growth factor activity in this second step. The FGF activity itself could be eluted using 2 M NaCl. Sephadex and subsequent heparin-Sepharose-purified growth factor fractions were analyzed by the SDS-PAGE, followed by silver staining or immunoblotting using polyclonal antibodies prepared against a bFGF peptide. Cells transformed by LD l/2 plasmid encoding the bovine bFGF/B-galactosidase fusion protein synthesized a protein of 20.5 kDa (Fig. 4a) , which is the expected size calculated from the encoded mRNA.
Recombinant human bFGF encoded by the plasmid T36/9 should have an J4, of 18 000 and a protein of approximately this size could be observed after induction (Fig. 4b) . Natural bovine brain bFGF served as a control (Fig. 4a ). An immunoreactive peptide of lower M,, probably a product of proteolytic degradation, was also detected using the antibody. Recombinant bovine bFGF fusion protein appeared as a doublet (Fig. 4a) , a phenomenon that has also been described for the brain-derived bovine bFGF (Lobb et al., 1986) .
FGF was also present in cytoplasmic inclusion bodies, as is often observed with other recombinant proteins expressed at a high level in E. coli (Kleid et al., 1981; Simons et al., 1984; Schoner et al., 1985) . Proteins in such inclusion bodies are generally soluble only under denaturing conditions. Thus, the pellet fraction obtained after centrifugation of lysed cells was solubilized in a large volume of guanidinium . HCl together with 0.2 M DTT to cleave possible intermolecular disulfide bonds. For renaturation the treated pellet fraction was carefully diluted and dialysed to prevent aggregation of bFGF. The cleared dialysate was directly applied to a heparin-Sepharose affinity column as described above.
(c) Biological activities of bovine and human recombinant fibroblast growth factor
The purified growth factors were analyzed for mitogenic activity on BAE cells. In this assay, the maximal stimulation observed with brain-derived bovine was similar to that with recombinant human (isolated from the supematant) 0.14 rig/ml] (Fig. 5) . The recombinant human bFGF isolated from the pellet fraction showed a somewhat lower ED,, of 0.5 ng/ml. The lower specific activity of the human bFGF pellet preparation might be due to the incomplete formation of disultide bonds that may be important to the correct conformation of bFGF (cf., e.g., aFGF; Thomas et al., 1988) . The recombinant bovine bFGF fusion protein showed an ED,, of 0.95 ng/ml, probably owing to the presence of additional p-galactosidase amino acids at the N terminus of the molecule.
We also examined the in vivo activity of recombinant bovine bFGF fusion protein and the human bFGF. In rabbit corneas, new sprouts originating from the limbal vascular system penetrated the avascular cornea two days after implantation of Elvax polymers cont~ning 500 ng of recombin~t human bFGF and reached the polymer ten days later (Fig. 6) . Similarly, recombinant bovine bFGF fusion protein stimulated angiogenesis in the rabbit cornea (not shown). No neovascularization was seen in corneas in which control polymers had been implanted. No inflammation was observed, except for an initial slight cloudiness of some corneas, which disappeared about four days after implantation. ED,,, 0.14 ng/ml; n , recombinant human bFGF, pellet (P) ED,,, 0.5 ng/ml. Biologically active recombinant bovine bFGF fusion protein and human bFGF encoded by chemically synthesized genes were isolated in high yield and high purity. They were obtained as a single band on SDS-PAGE (Fig. 4a,b) . Quantitation of the expressed growth factors was carried out using the Biorad protein assay. The described plasmid constructions in the selected E. coli strains directed the synthesis of 0.5 mg bovine bFGF protein and 5 mg human bFGF protein per liter culture medium per 1 AhOOnm isolated from the soluble fraction of the cell extracts.
Three to four times the quantity of biologically active growth factor protein could certainly be obtained from the insoluble material that is also present in the induced cells. This would necessitate the successful renaturation of solubilized inclusion bodies. Large quantities of recombinant bFGF should help us to elucidate the biological function of bFGF in vivo as well as to investigate its potential application under pathological conditions such as wound healing (Sprugel et al., 1988) nerve regeneration (Baird et al., 1988) , and cardiac infarction.
